COLL Stock Earnings Collegium Pharmaceutical Beats EPS, Beats Revenue for Q2 2024

COLL Stock  USD 30.50  0.21  0.68%   
About 67% of Collegium Pharmaceutical's investor base is looking to short. The analysis of overall sentiment of trading Collegium Pharmaceutical stock suggests that many investors are alarmed at this time. Collegium Pharmaceutical's investing sentiment shows overall attitude of investors towards Collegium Pharmaceutical.
  
COLL stock results show that Collegium Pharmaceutical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Read at investorplace.com
sbwire news
  

Collegium Pharmaceutical Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Collegium Pharmaceutical can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Collegium Pharmaceutical Fundamental Analysis

We analyze Collegium Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Collegium Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Collegium Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Cash Flow From Operations

Cash Flow From Operations Comparative Analysis

Collegium Pharmaceutical is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

Collegium Pharmaceutical Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Collegium Pharmaceutical stock to make a market-neutral strategy. Peer analysis of Collegium Pharmaceutical could also be used in its relative valuation, which is a method of valuing Collegium Pharmaceutical by comparing valuation metrics with similar companies.

Peers

Collegium Pharmaceutical Related Equities

ELDNEledon Pharmaceuticals   9.39   
0%
100.0%
CNTBConnect Biopharma   2.91   
0%
30.0%
ABOSAcumen Pharmaceuticals   0.44   
0%
4.0%
NUVBNuvation Bio   0.35   
0%
3.0%
REPLReplimune   0.21   
0%
2.0%
CELCCelcuity LLC   0.39   
4.0%
0%
INBXInhibrx   2.37   
25.0%
0%
ELVNEnliven Therapeutics   4.05   
43.0%
0%
NVCTNuvectis Pharma   4.55   
48.0%
0%
ELYMEliem Therapeutics   5.88   
62.0%
0%
When determining whether Collegium Pharmaceutical is a strong investment it is important to analyze Collegium Pharmaceutical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Collegium Pharmaceutical's future performance. For an informed investment choice regarding Collegium Stock, refer to the following important reports:
Check out Collegium Pharmaceutical Hype Analysis, Collegium Pharmaceutical Correlation and Collegium Pharmaceutical Performance.
For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.
You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.49)
Earnings Share
2.34
Revenue Per Share
18.538
Quarterly Revenue Growth
0.165
Return On Assets
0.0968
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.